Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa dose-finding trial of Renzhu Changle Granule for diarrhea-predominant irritable bowel syndrome
ChiCTR1800018076Phase 2Recruiting
- Sponsor
- Capital Medical University
- Start
- Sep 2018
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Renzhu Changle Granule in Diarrhea-predominant irritable bowel syndrome (IBS-D) (3 arms), sponsored by Capital Medical University. Primary endpoints: Abdominal pain intensity response rate, Fecal trait response rate and 2 more. Started Sep 2018; status: recruiting.
02
Drugs
Renzhu Changle Granule
03
Conditions
Diarrhea-predominant irritable bowel syndrome (IBS-D)
Beyond the preview
Go deeper on ChiCTR1800018076.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800018076.